Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012

Journal of Clinical Oncology

Volumn 29, Issue 8, 2011, Pages 1014-1021

  Ellis, Georgiana K ^a   Barlow, William E ^a   Gralow, Julie R ^a   Hortobagyi, Gabriel N ^a   Russell, Christy A ^a   Royce, Melanie E ^a   Perez, Edith A ^a   Lew, Danika ^a   Livingston, Robert B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; AGITATION; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG INDUCED HEADACHE; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; INFLAMMATORY BREAST CANCER; INTESTINE OBSTRUCTION; LETHARGY; LEUKOPENIA; LOCALLY ADVANCED BREAST CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ODDS RATIO; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; YOUNG ADULT;

EID: 79952771912     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.6543     Document Type: Article

References (20)

1. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984 (Pubitemid 15202705)
2. Hryniuk WM, Levine MN, Levin L: Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1:87-94, 1986 (Pubitemid 17200850)
3. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986 (Pubitemid 16043865)
4. Ellis GK, Livingston RB, Gralow JR, et al: Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 20:3637-3643, 2002 (Pubitemid 34983223)
5. Ellis G, Green S, Livingston R, et al: Neoadjuvant doxorubicin, cyclophosphamide and G-CSF (AC+G) for locally advanced breast cancer (LABC), a Southwest Oncology Group phase II study. Proc Am Soc Clin Oncol 19:85a, 2000 (suppl: abstr 326)
6. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
7. Man S, Bocci G, Francia G, et al: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735, 2002 (Pubitemid 34525751)
8. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992, 2005
9. Ellis GK, Green SJ, Russell CA, et al:SWOG0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 24:12s, 2006 (suppl; abstr LBA537)
10. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: A review. J Clin Oncol 10:1014-1024, 1992
11. Cristofanilli M, Buzdar AU, Sneige N, et al: Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92:1775-1782, 2001 (Pubitemid 32952495)
12. Hortobagyi GN, Singletary SE, Buchholz TA: Locally advanced breast cancer, in Singletary SE, Robb GL, Hortobagyi HN (eds): Advanced Therapy of Breast Disease (ed 2). Hamilton, Ontario, Canada, BC Decker, 2000
13. von Minckwitz G, Raab G, Caputo A, et al: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685, 2005 (Pubitemid 46179457)
14. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
15. Stearns V, Singh B, Tsangaris T, et al: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9:124-133, 2003 (Pubitemid 36109724)
16. Mancuso MR, Davis R, Norberg SM, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621, 2006 (Pubitemid 44511625)
17. Natori T, Sata M, Washida M, et al: G-CSF stimulates angiogenesis and promotes tumor growth: Potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297:1058-1061, 2002 (Pubitemid 35230360)
18. Kleer CG, van Golen KL, Merajver SD: Molecular biology of breast cancer metastasis: Inflammatory breast cancer - Clinical syndrome and molecular determinants. Breast Cancer Res 2:423-429, 2000 (Pubitemid 32223639)
19. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005 (Pubitemid 40740554)
20. Mackey JR, Paterson A, Dirix LY, et al: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cycclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:35a, 2002 (suppl: abstr 137)